AUTHORS
Clifton C. Mo, MD, Cristina Gasparetto, MD2, Cristiana Chase3, Rahul Banerjee, MD, FACP4, Tomer Mark, MD5, Yi Chai6, Trinayan Kashyap, MS7, Jessica Katz, MD, PhD8, Michael Amatangelo, PhD9, Paul G. Richardson, MD10
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Duke University Health System, Durham, North Carolina, United States
3 Duke University Health System, Durham, North Carolina, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Karyopharm Therapeutics, Newton, Massachusetts, United States
6 Karyopharm Therapeutics, Newton, Massachusetts, United States
7 Karyopharm Therapeutics, Newton, Massachusetts, United States
8 Bristol Myers Squibb, Princeton, New Jersey, United States
9 Bristol Myers Squibb, Princeton, New Jersey, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Background: While CAR T therapy and bispecific antibodies are powerful options for RRMM, there is an unmet need for clinical strategies to maintain and recapture response after T-cell–redirecting therapy (TCRT) failure or to induce responses in TCRT-ineligible patients (pts). Both selinexor (S, an oral exportin 1 [XPO1] inhibitor) and mezigdomide (M, a novel, oral, and potent cereblon E3 ubiquitin ligase modulator [CELMoD]) have shown T-cell preservation and stimulatory activity, which may recapture responses after TCRT failure or may prime T cells for subsequent TCRT. We present updated results from Arm 12 of the Phase 1b/2 STOMP trial (NCT02343042) investigating SMd in pts with RRMM for whom TCRT has failed or who otherwise cannot receive TCRT.
Methods: STOMP Arm 12 is evaluating SMd in adults with triple-class exposed RRMM with ≥2 prior lines of therapy and who had progressed after or were deemed ineligible for TCRT. All study drugs were administered orally. Phase 1 had 3 cohorts with S dose escalated from 40 mg once weekly to 60 mg on days 1, 8, and 15 of a 28-day cycle; M was administered at 0.6 or 1.0 mg daily on days 1–21, and dexamethasone (d) 40 mg was administered weekly. Responses were assessed by investigator using International Myeloma Working Group criteria, and safety was assessed per Common Terminology Criteria for Adverse Events (CTCAE) V5.0. Phase 1 objectives were to determine maximum tolerated dose and recommended Phase 2 dose (RP2D) of SMd; Phase 2 primary objectives were to determine objective response rate (ORR) and further characterize safety as per CTCAE V5.0 at the RP2D.
Results: Seventeen pts were enrolled (Phase 1: n=13, Phase 2: n=4): 3 pts were treated at dose level 1 (S40, M0.6), 7 at dose level 2 (S60, M0.6), and 7 at dose level 3 (S60, M1.0). Median age was 66 years, 58.8% (10/17) were male, and median time from initial MM diagnosis was 9.1 yrs. Pts had a median 5 prior lines of therapy; 13/17 (76.5%) were triple-class refractory. Four pts each (23.5%) had prior belantamab mafodotin, CAR-T, and bispecific antibody treatment.
No dose-limiting toxicities (DLTs) were observed in cohorts 1 or 2; two DLTs occurred at dose level 3 (grade 2 constipation/proctitis and grade 4 neutropenia). The RP2D was identified as dose level 2: S60, M0.6. At data cutoff, median duration of treatment across the cohorts was 5.2 months, with a median on-study duration of 8.7 months.
Treatment-emergent adverse events (TEAEs) were consistent with the known safety profiles of S and M, with no new safety signals reported. The most common TEAEs were neutropenia (85%), thrombocytopenia (62%), constipation (54%), and leukopenia (54%); grade 3/4 neutropenia occurred in 54%. There was one treatment-related death secondary to hypoxic respiratory failure from multifocal pneumonia in the setting of febrile neutropenia in dose level 3 and one death due to disease progression at dose level 2.
As of July 7, 2026, 16 pts had ≥1 performed response assessment. The investigator-assessed ORR was 52.9% (9/17), with ≥ very good partial response in 35.3% (6/17). Median time to ≥ partial response was 28 days (range 28–140), and median time to best response was 95 days (range 28–280). Median progression-free survival was 3.4 months (0.5–17.7 months), and median duration of response was 10.6 months (1.9–15.9 months).
Longitudinal immunoprofiling of bone marrow aspirates and peripheral blood revealed that SMd treatment drove T-cell proliferation and activation, as evidenced by median increases in IL-2 and IL-21 levels. SMd led to increased Ki67 expression and downregulation of PD-1 and TIGIT on CD8+ T cells alongside attenuation of pro-inflammatory cytokines, including IL-6, IL-8, and TNFα. Clinical response to SMd was associated with effector T-cell expansion and a reduction in immunosuppressive cell populations; updated analyses will be presented at the meeting.
Conclusions: TEAEs overall were consistent with AE profiles for S and M, with no new safety signals detected. SMd was effective in heavily pretreated pts with RRMM who had relapsed after or were ineligible for TCRT, with objective and durable responses observed in over half of treated pts. The all-oral, T-cell–stimulating, SMd regimen may address a need for salvage or bridging therapies before, after, or in between TCRT, as well as for pts in whom TCRT may not be feasible and/or appropriate.
DISCLOSURES
Clifton C. Mo, MD: Regeneron - Honoraria; Kryopharm - Honoraria; Johnson & Johnson - Honoraria; GSK - Honoraria; Sanofi - Research Funding; Regeneron - Research Funding; BMS - Research Funding; GSK - Consultancy (Includes expert testimony)